Sunvozertinib for untreated advanced non-small cell lung cancer with uncommon EGFR mutations
Official title: a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Run by Fudan University · NCT07117890 · Data updated 2026-11-12
This will test whether the oral drug sunvozertinib can shrink tumors and be safe in adults with untreated advanced non‑small cell lung cancer who have uncommon EGFR mutations.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 34 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | sunvozertinib |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | February 7, 2025 |
| Main results expected | February 20, 2027 |
| Study ends | May 30, 2027 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07117890 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with untreated advanced non-squamous NSCLC, a documented uncommon EGFR mutation (not exon 19del, L858R, T790M, or exon 20 insertion), measurable disease by RECIST 1.1, and a predicted life expectancy of at least 12 weeks are the intended participants.
✕Probably not a fit
Patients with common EGFR mutations (exon 19del, L858R, T790M, or exon 20 insertions), prior systemic anti-tumor therapy, squamous histology, recent other malignancies, active infections, or uncontrolled severe systemic disease are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm Phase 2 trial enrolling adults with untreated advanced non-squamous NSCLC who carry documented uncommon EGFR mutations (excluding exon 19 deletion, L858R, T790M, and exon 20 insertions). Eligible participants receive oral sunvozertinib at specified doses (200 mg or 300 mg) and are followed with regular imaging and clinical assessments. Tumor response will be measured by RECIST 1.1 and safety will be monitored through adverse event reporting and labs. The study is conducted at Fudan University Shanghai Cancer Center and focuses on anti-tumor activity and tolerability in this molecularly defined group.
Why it matters
Potential benefit: If successful, sunvozertinib could provide a targeted oral treatment that controls tumors for patients with uncommon EGFR mutations who currently have limited tailored options.
How similar studies have gone: Other EGFR tyrosine kinase inhibitors have shown activity for some uncommon EGFR mutations but responses are variable, so testing sunvozertinib in this setting is partially supported by prior work yet remains relatively novel for many mutation types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥18 years old 2. histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations. 3. predicted life expectancy ≥ 12 weeks. 4. patient must have measurable disease according to RECIST 1.1 Exclusion Criteria: 1. previos systemic anti-tumor therapy 2. a history of malignant tumors within 2years 3. any severa or poorly controlled systemic disease per investigator's judgement 4. active infections
Where it's running
-
Fudan university shanghai cancer center
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jialei Wang
- Email: wangjialei@shca.org.cn
- Phone: 18017312369
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sunvozertinib as follow-up treatment after surgery for early-stage NSCLC with EGFR exon 20 insertion or PACC mutations
This trial tests whether taking sunvozertinib after complete surgery can lower the chance of cancer coming back in adults with stage IB–IIIA non-small cell lung cancer whose tumors have EGFR exon 20 insertion or PACC mutations.
-
DZD6008 plus sunvozertinib for advanced EGFR‑mutant non‑small cell lung cancer
This will test whether combining oral EGFR inhibitor DZD6008 with sunvozertinib is safe and helps shrink tumors in adults with advanced EGFR‑mutant non‑small cell lung cancer.
-
Combination treatment for advanced lung cancer with specific mutations
This study is testing a new combination of two drugs to see if it can help people with advanced lung cancer who have certain genetic mutations live longer without their cancer getting worse.
-
Combination treatment for advanced lung cancer with specific mutations
This study is testing a new combination of two drugs for people with advanced lung cancer who have specific genetic mutations to see if it helps them live longer without their cancer getting worse.
-
Combining Sunvozertinib with chemotherapy for advanced lung cancer after TKI failure
This study is testing if combining a new drug called Sunvozertinib with chemotherapy can help people with advanced lung cancer who didn't respond to previous treatments.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.